| North China Pharmaceutical Group Corp. (NCPC) is a leading armaceutical manufacturer in China. NCPC, in its early days, was one of the key construction projects during Chinese First Five-Year Plan. After fiver years of construction from the foundation date in June 1953 , the successful operation started in June 1958. Being one of the world leading antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotic in China. With 45 years?÷ development, NCPC has been continually growing and taking the lead in China pharmaceutical industry in key economic indexes, ranking one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets is USD2 billion, number of employees 18500. In 2002, NCPC achieved domestic sales revenue USD 700million and export sales USD100million. Sticking to the spirit of "Service for Life ", NCPC is willing to build bright future for all the people.
NCPC now has 29 subsidiaries. Among which North China Pharmaceutical Co., Ltd. is a listed company at Shanghai Stock Exchange with 59.87% of shaires held by NCPC. NCPC is one of the four groups of the candidate enterprises approved by China Securities Regulatory Commission for overseas listing. Keeping in close cooperation with foreign companies and institutions, NCPC has established 16 joint ventures and cooperative ventures.
NCPC currently produces over 430 kinds of antibiotics, semi-synthetic antibiotics, pharmaceutical intermediates, vitamins, biotechnology products, veterinary and neutraceuticals both in bulk and in finished products. NCPC sells bulk antibiotics 7000tons, vitamins 10000tons, antibiotic intermediates 7500tons, powder for injection 1.8 billion vials, capsules 1.03 billion grains annually. The capacity of penicillin, streptomycin, 6-APA, amoxycillin, cefaradine, vitamin B100 are in the lead worldwide. NCPC's next development focus is on biotechnology products, bio-pesticides and animal products. Since 1984, NCPC has initiated research on modern biotechnology and formed the system for developing generic drug involving new products R&D, pilot production and commercial production. In cooperation with the foreign companies, NCPC has completed the design and construction of GeneTech Biotechnology Co., Ltd. who is now a modern biotechnology production base in line with international practice and standards. There are rhGM-CSF, rhG-CSF, EPO and Hepatitis B Vaccine (CHO) on market at present.
Address:388 Heping Donglu,Shijiazhuang,P.R.China
Postalcode:050015
Telephone:0311-86677982-810 85992728
Fax:0311-85051711
Email: office@ncpcie.com |
